EU Commission's SCENIHR casts fresh eye over PIP implant safety, MoM hips
This article was originally published in Clinica
Executive Summary
SCENIHR, the European Commission’s scientific committee that assesses emerging and newly identified health risks, is to give a second opinion in June on the safety of the controversial PIP silicone gel breast implants. The devices, which were filled with industrial-grade silicone and sold worldwide, became the centre of a public health storm at end of 2011 and threw the medtech industry - and the revision on the medical device directives - into turbulent waters last year.
You may also be interested in...
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.
First Danish Notified Body Named Under EU's Medical Device Regulation
The EU now has a total of 45 notified bodies under the MDR.